Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20754456 | 1.00 | CYP1A2 (0.45) | CYP1A2CYP2D6MAPTKMT2ALMNA | |
| SCHEMBL20754698 | 0.90 | MMP8 (0.41) | CYP1A2CYP2D6MAPTKMT2ALMNA | |
| SCHEMBL20746341 | 0.89 | SMN1; SMN2 (0.51) | CYP1A2CYP2D6MAPTKMT2ALMNA | |
| SCHEMBL20746339 | 0.89 | SMN1; SMN2 (0.51) | CYP1A2CYP2D6MAPTKMT2ALMNA | |
| SCHEMBL20746553 | 0.87 | GAA (0.53) | MAPTKMT2ALMNANPSR1MEN1 | |
| SCHEMBL20746574 | 0.87 | NPC1 (0.51) | MAPTKMT2ALMNANPSR1MEN1 | |
| SCHEMBL20746552 | 0.87 | GAA (0.53) | MAPTKMT2ALMNANPSR1MEN1 | |
| SCHEMBL20746436 | 0.86 | KMT2A (0.51) | CYP1A2MAPTKMT2ALMNANPSR1 | |
| SCHEMBL20746435 | 0.86 | KMT2A (0.51) | CYP1A2MAPTKMT2ALMNANPSR1 | |
| SCHEMBL20746541 | 0.86 | SMN1; SMN2 (0.52) | CYP1A2CYP2D6MAPTKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385374-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF TOLEDO (US) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385374-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | HDAC1, HDAC8, HDAC2 | CYP1A2 3217/4885CYP2D6 4213/4885MAPT 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.